Tounjian Advisory Partners’s AstraZeneca AZN Stock Holding History

Tounjian Advisory Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.56K	Buy	+24	New	+$4.51K	﹤0.01%	458

Other funds holding AZN

EPGL

Evelyn Partners Group Ltd London $46.9B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

Tounjian Advisory Partners's AZN Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in AstraZeneca (AZN) in Q2 2026: 24 shares worth $4.56K. The stake represents ﹤0.01% of the portfolio and ranks #458 among its holdings.

977 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Tounjian Advisory Partners held 24 shares of AstraZeneca worth $4.56K as of Q2 2026.
AstraZeneca was a new Tounjian Advisory Partners position in Q2 2026.
AstraZeneca made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #458 holding.
977 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.